What is happening with Surface Oncology (SURF) stock?

Related Topics


Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies and using biological pathways to target the tumor microenvironment, announced the appointment of a new chief business officer, Henry Rath. Furthermore, Alison O’Neill was promoted to the chief medical officer and Jessica Fee to the chief financial officer. Surf stock price saw no variation adjacent to the news.

At last check in current market trading, shares of Surface Oncology Inc. (SURF) gained 0.68% $7.45. SURF stock closed the last session at $7.40, increasing 5.56% or $0.39. Shares of Surface Oncology inc fluctuated between $7.05 and $7.52 throughout the day.  It traded 1.14 million shares, which was below its daily average of 1.6 million shares over 100 days.

About Surface Oncology

Surface Oncology has currently collaborated with two pharmaceutical companies. The first partnership with Novartis targets CD73 (NZV930; Phase 1), while the second partnership with GlaxoSmithKline is presently targeting PVRIG (SRF813; preclinical).SURFpipeline is inclusive of two clinical-stage assessments focusing on CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program specializing in reducing regulatory T cells through targeting CCR8 (SRF114)

Surface oncology has also been recognized by the Boston Business Journal as one of the Best Places to Work in 2021. Employees were asked to rate the company culture, work-life synergy, job satisfaction, the opportunity for career growth, and benefits. SURF met the criteria and will be awarded at a virtual celebration on June 16th.

Furthermore, newly appointed Chief Business Officer, Henry brings more than two decades of experience in the biotechnology industry, working in various roles such as corporate finance, strategy, commercial planning, and business development. Henry started his early career working in roles of banking and consulting industries, focusing on biotechnology with Oppenheimer & Co. and LEK Consulting. He earned his undergraduate degree from the well-esteemed Harvard university after which he did his MBA from Wharton University.

Chief Financial officer Jessica Fees also brings more than two decades of experience in finance and operations, serving roles such as president of Glide Consulting and held senior positions at Aileron Therapeutics and Tokai Pharmaceuticals.


Several collaborations with pharmaceutical companies combined with company executives with immense knowledge and experience has peaked investor expectation for the company. Furthermore, positive work culture has been extremely significant for the company to reach its objectives.

Leave a Comment

Your email address will not be published.

Latest Posts